Preoperative low skeletal muscle volume can result in insufficient administration of S-1 adjuvant chemotherapy in older patients with stage II/III gastric cancer

被引:1
|
作者
Kono, Yusuke [1 ]
Matsunaga, Tomoyuki [1 ]
Makinoya, Masahiro [1 ]
Shimizu, Shota [1 ]
Shishido, Yuji [1 ]
Miyatani, Kozo [1 ]
Kihara, Kyoichi [1 ]
Yamamoto, Manabu [1 ]
Takano, Shuichi [1 ]
Tokuyasu, Naruo [1 ]
Sakamoto, Teruhisa [1 ]
Hasegawa, Toshimichi [1 ]
Fujiwara, Yoshiyuki [1 ]
机构
[1] Tottori Univ, Sch Med, Dept Surg, Div Surg Oncol,Fac Med, 36-1 Nishi Cho, Yonago 6838504, Japan
关键词
Gastric cancer; Adjuvant chemotherapy; Sarcopenia; Elderly; S-1; ANAMORELIN;
D O I
10.1007/s00595-023-02737-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and purposeOlder patients are more likely to encounter difficulties receiving chemotherapy, but the factors involved in the continuation of chemotherapy in these patients remain unclear. We investigated the importance of muscle mass as a factor involved in delivering a sufficient dose of postoperative S-1 adjuvant chemotherapy (ACT) to older patients with gastric cancer.MethodsThe subjects of this study were 79 patients aged & GE; 65 years with stage II/III gastric adenocarcinoma, who underwent curative gastrectomy and received S-1 ACT.ResultsThe overall median relative dose intensity (RDI) was 75.0% (18.8-93.5%). Patients were divided into two groups for receiver operating characteristic analysis according to the cutoff value. Significantly more patients in the high skeletal muscle index (SMI) group achieved > 62% RDI of S-1 ACT (p = 0.03). Conversely, more patients in the low SMI group suffered from S-1-induced nausea (p = 0.03) and discontinued chemotherapy because of adverse events (p = 0.02). Multivariate analysis identified low SMI as an independent factor for insufficient S-1 dose delivery (p = 0.03, hazard ratio = 2.87).ConclusionPreoperative SMI is an indicator of the low-dose intensity of S-1 ACT in older patients following curative gastrectomy.
引用
收藏
页码:340 / 346
页数:7
相关论文
共 50 条
  • [1] Preoperative low skeletal muscle volume can result in insufficient administration of S-1 adjuvant chemotherapy in older patients with stage II/III gastric cancer
    Yusuke Kono
    Tomoyuki Matsunaga
    Masahiro Makinoya
    Shota Shimizu
    Yuji Shishido
    Kozo Miyatani
    Kyoichi Kihara
    Manabu Yamamoto
    Shuichi Takano
    Naruo Tokuyasu
    Teruhisa Sakamoto
    Toshimichi Hasegawa
    Yoshiyuki Fujiwara
    Surgery Today, 2024, 54 : 340 - 346
  • [2] The impact of preoperative skeletal muscle loss on the completion of S-1 adjuvant chemotherapy for gastric cancer
    Nakabayashi, Yudai
    Ohashi, Takuma
    Kubota, Takeshi
    Nishibeppu, Keiji
    Yubakami, Masayuki
    Konishi, Hirotaka
    Shiozaki, Atsushi
    Fujiwara, Hitoshi
    Otsuji, Eigo
    SURGERY TODAY, 2025, 55 (02) : 238 - 246
  • [3] Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer
    Kozo Miyatani
    Hiroaki Saito
    Shota Shimizu
    Yusuke Kono
    Yuki Murakami
    Yuji Shishido
    Tomoyuki Matsunaga
    Yoji Fukumoto
    Yoshiyuki Fujiwara
    International Journal of Clinical Oncology, 2019, 24 : 1190 - 1196
  • [4] Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer
    Miyatani, Kozo
    Saito, Hiroaki
    Shimizu, Shota
    Kono, Yusuke
    Murakami, Yuki
    Shishido, Yuji
    Matsunaga, Tomoyuki
    Fukumoto, Yoji
    Fujiwara, Yoshiyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (10) : 1190 - 1196
  • [5] Outcome predictors for patients with stage II/III gastric cancer who undergo gastrectomy and S-1 adjuvant chemotherapy
    Fujiwara, Yoshinori
    Fukuda, Shuichi
    Tsujie, Masanori
    Kitani, Kotaro
    Inoue, Keisuke
    Hayashi, Tomonori
    Ishikawa, Hajime
    Yukawa, Masao
    Inoue, Masatoshi
    ONCOLOGY LETTERS, 2017, 14 (02) : 1621 - 1627
  • [6] Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
    Noriyuki Hirahara
    Takeshi Matsubara
    Shunsuke Kaji
    Tetsu Yamamoto
    Ryoji Hyakudomi
    Kiyoe Takai
    Kazunari Ishitobi
    Yuki Uchida
    Yoshitsugu Tajima
    BMC Cancer, 21
  • [7] Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
    Hirahara, Noriyuki
    Matsubara, Takeshi
    Kaji, Shunsuke
    Yamamoto, Tetsu
    Hyakudomi, Ryoji
    Takai, Kiyoe
    Ishitobi, Kazunari
    Uchida, Yuki
    Tajima, Yoshitsugu
    BMC CANCER, 2021, 21 (01)
  • [8] Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer
    Tsujimoto, Hironori
    Horiguchi, Hiroyuki
    Hiraki, Shuichi
    Yaguchi, Yoshihisa
    Takahata, Risa
    Kumano, Isao
    Yoshida, Kazumichi
    Matsumoto, Yusuke
    Ono, Satoshi
    Yamamoto, Junji
    Hase, Kazuo
    ONCOLOGY LETTERS, 2012, 4 (05) : 1135 - 1139
  • [9] Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1
    Watanabe, Hayato
    Hayashi, Tsutomu
    Komori, Keisuke
    Hara, Kentaro
    Maezawa, Yukio
    Kano, Kazuki
    Shimoda, Yota
    Fujikawa, Hirohito
    Aoyama, Toru
    Yamada, Takanobu
    Yamamoto, Naoto
    Cho, Haruhiko
    Ito, Hiroyuki
    Shiozawa, Manabu
    Yukawa, Norio
    Morinaga, Soichiro
    Yoshikawa, Takaki
    Rino, Yasushi
    Masuda, Munetaka
    Ogata, Takashi
    Oshima, Takashi
    ANTICANCER RESEARCH, 2020, 40 (03) : 1683 - 1690
  • [10] Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection
    Mita, Kazuhito
    Ito, Hideto
    Ota, Emi
    Takahashi, Koudai
    Hashimoto, Masatoshi
    Asakawa, Hideki
    Hayashi, Takashi
    Fujino, Keiichi
    ANTICANCER RESEARCH, 2017, 37 (03) : 1329 - 1333